In his tenure as US FDA Commissioner, Scott Gottlieb has demonstrated an unsurpassed gift for conveying a sense of progress at the agency in the context of even the most complex or technical of regulatory actions.
But in announcing FDA’s final guidance on the so-called “deeming” process – under which about a dozen ingredients currently approved...